Changes for page Torrent Pharmaceuticals Ltd

Last modified by Asif Farooqui on 2021/09/20 18:50

From version < 7.1 >

edited by Asif Farooqui
on 2021/09/20 18:29

To version < 7.2 >

edited by Asif Farooqui
on 2021/09/20 18:40

< >

Change comment: There is no comment for this version

Raw
Rendered

Summary

Page properties (1 modified, 0 added, 0 removed)

Details

Page properties

Content

@@ -126,16
+126,15 @@
  [[image:TORNTPHARM4.jpg]]
--Business Overview
++= Business Overview =
--Torrent Pharma blazed a new trail in the Indian Pharmaceuticals industry by successfully implementing the concept of niche marketing. Torrent Pharmaceuticals was the pioneers in initiating the concept of niche marketing and today, is ranked amongst the leaders in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI) and women healthcare (WHC). The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments.
++Torrent Pharma blazed a new trail in the Indian Pharmaceuticals industry by successfully implementing the concept of niche marketing. Torrent Pharmaceuticals was the pioneers in initiating the concept of niche marketing and today, is ranked amongst the leaders in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI) and women healthcare (WHC). The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments.{{footnote}}https://torrentpharma.com/index.php/site/info/businessAreas{{/footnote}}
--[[https:~~/~~/torrentpharma.com/index.php/site/info/businessAreas>>url:https://torrentpharma.com/index.php/site/info/businessAreas]]
  Torrent Pharma also has a strong international presence spread across 40 countries with operations in regulated and emerging markets like US, Europe, Brazil and Rest of the World. The Company operate through its wholly owned subsidiaries spread across 12 nations with major setups in Brazil, Germany and US.
--India Business
++== India Business ==
  Right from pioneering niche marketing in India to earning the sobriquet of 'The Company with the Most First Launches,' Torrent Pharma has established itself as a major player in the Indian Pharma arena. Torrent Pharmaceuticals has well segregated marketing divisions, strategically structured on specific therapeutic areas and enjoys dominance in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI) and women healthcare (WHC). The company's vast field force of more than 3600 personnel cater to 1.70 Lakh Doctors across the country. Torrent Pharma has a strong domestic presence in India with modern manufacturing facilities and cutting edge R & D Center. Revenues in India was Rs. 3,739 Cr. in 2020 – 2021. Torrent Pharma reaches the target market segments through 22 sales divisions with a wide customer coverage through 5000+ stockists and 59000 retailers serviced through 22 distribution centres across India.
@@ -143,8
+143,11 @@
  With Unichem's domestic business acquisition, Torrent has entered the list of top pharma firms in the Indian Pharma Market (IPM) and is ranked No 8 in the IPM.
--US Business
++[[image:TORNTPHARM6.png]]
++
++== US Business ==
++
  The world’s largest market for pharmaceuticals, USA has always been on Torrent Pharma’s strategic radar. Torrent Pharma Inc., its subsidiary, serves the growing need of its products in the market and today Torrent Pharmaceuticals is ranked 10th amongst the US generic Indian Companies.
@@ -154,19
+154,16 @@
  Torrent has strengthened the US presence through acquisition of Bio-Pharm, Inc. (BPI) a generic pharmaceuticals and OTC Company, based in Levittown Pennsylvania, USA, which includes, its first overseas US FDA registered manufacturing facility.
++== International Business ==
--International Business
++**EUROPE**
--EUROPE
++One of the most regulated and evolved Pharma markets worldwide, the EU has been a veritable learning ground for Torrent. Proven expertise in product development and a strong regulatory knowledge have helped in developing a highly robust product portfolio comprising of different TAs including CNS, CVS and GI among others. The company's wholly owned subsidiaries in Germany and UK, spearhead Torrent Pharma’s operations in the EU territory. Both the markets have shown impressive growth over the last 5 years.{{footnote}}https://torrentpharma.com/index.php/site/info/business_international{{/footnote}}
--One of the most regulated and evolved Pharma markets worldwide, the EU has been a veritable learning ground for Torrent. Proven expertise in product development and a strong regulatory knowledge have helped in developing a highly robust product portfolio comprising of different TAs including CNS, CVS and GI among others. The company's wholly owned subsidiaries in Germany and UK, spearhead Torrent Pharma’s operations in the EU territory. Both the markets have shown impressive growth over the last 5 years.
--[[https:~~/~~/torrentpharma.com/index.php/site/info/business_international>>url:https://torrentpharma.com/index.php/site/info/business_international]]
++**Germany**
--
--Germany
--
  Torrent forayed into Germany in 2005 with acquisition of Heumann Pharma Generics, a Pfizer Group Company. Heumann’s broad product portfolio coupled with its low-cost manufacturing facilities provide a good strategic market position to it in one of the biggest pharmaceutical markets in the globe.
@@ -173,12
+173,12 @@
  Today, Torrent enjoys 4th position in the market and is ranked No. 1 amongst the Indian players in the market.
--UK
++**UK**
  Torrent Pharma (UK) Ltd is one of the fastest growing generic pharmaceutical companies within the UK; the most mature generics market in Western Europe. Through robust supplies from Torrent Pharmaceuticals and several portfolio acquisition deals, Torrent Pharmaceuticals has built a robust pipeline of products and a current range of over 100 molecules.
--Brazil
++**Brazil**
  Torrent entered the Brazilian market 16 years ago. Currently, ranked 1st in covered market, it is ranked 15th in prescriptions exhibiting the 5th highest growth in branded products amongst the top 50 Pharmaceuticals companies in the Country. Torrent is also the biggest Indian Company in terms of sales in Brazil contributing to almost 65% of sales by Indian companies in Brazil. The company's strong relationship with Neurologists, Psychiatrists and Cardiologists have helped it accomplish the same.
@@ -192,44
+192,44 @@
  Emerging markets is a mix of regulated and semi regulated markets comprising of Russia, CIS, South East Asia, Asia Pacific, Africa, Middle East, Central and Latin America. Torrent Pharma’s products in the Therapeutic areas of Diabetology, Cardiovascular and Central Nervous System are promoted and supported by its sales and support team of over 450 people.
--<img map>
++[[image:TORNTPHARM7.png]]
--AFRICAN COUNTRIES
++=== African Countries ===
--Zimbabwe
++**Zimbabwe**
  Torrent has the distinction of being one of the foremost Indian Company to get its products registered in this market and is also amongst the leading Indian company in the Zimbabwean market. With a rich portfolio of 35 products and a strong pipeline of 10 products under registration, Torrent Pharmaceuticals is well poised to extract the high potential offered by this market.
--Kenya
++**Kenya**
  Kenya being the gateway to East African Markets is a territory of strategic significance for Torrent. Having started its marketing operations in 1994, the past couple of years have witnessed consolidation of the marketing efforts. With 45-product registered and 12 more in the offing, its focus is on brand building.
--Uganda
++**Uganda**
  Strategic selection of products encompassing a wide range of therapeutic indications has found profound acceptance by the members of medical fraternity in this country. The aim is to intensify Torrent's focus on Cardio Vascular and CNS products, which has been its forte over the years. Present product portfolio entails an assortment of 33 products with 8 more in pipeline.
--Nigeria
++**Nigeria**
  Extending its territorial fortification to Western Africa, Torrent made successful forays into Nigeria, which by far is one of the biggest markets in West Africa. Having already secured registrations for a handful of its specialized products, Torrent is all set to explore this attractive market with 30 products in pipeline.
--South Africa
++**South Africa**
  Having received SA MCC’s approval for the manufacturing facility of Oral Solids and about 15 product registrations, Torrent’s pathway is open to explore Africa’s sizeable and the most regulated market.
--ASIAN COUNTRIES
++=== Asian Countries ===
--Srilanka
++**Srilanka**
  Torrent's consistent sales growth over the past decade displays the confidence of medical fraternity in its brands. With over 55 products in the market and another 15 in the pipeline, the company remain committed towards providing a wide range of products to the Sri Lankan market. Torrent is well known in the island for its neuro-psychiatry, cardio vascular and gastro intestinal range.
--Vietnam
++**Vietnam**
  Vietnam is one of the major market in the South East Asian arena for Torrent. Currently, 55 products are registered and 15 are in pipeline. The company started its operations in Vietnam in the year 1996, with representative office in Ho Chi Minh City, the commercial capital of Vietnam.
@@ -237,7
+237,7 @@
  Torrent in Vietnam now has a mixed basket of products, with a focus on brand building to ensure long-term business & growth. In continuation of its Indian tradition, Torrent has earned a distinct image for itself in Vietnam in the field of cardiology & neuropsychiatry.
--Myanmar
++**Myanmar**
  Torrent Pharma initiated the marketing operations in Myanmar in 1995. Torrent Pharmaceuticals has more than 50 products registered in the country with another 20 in the pipeline. Four distributors across the country distribute its registered products.
@@ -248,29
+248,29 @@
  The company's focus is on strengthening the product basket, creating brand equity and launching new molecules in the market.
--Philippines
++**Philippines**
  Torrent’s first subsidiary in Asia has been in Philippines considering the marketing opportunities available in this densely populated island nation. Today, Torrent is amongst the top 20 companies in the country and is the No. 1 branded Generic Company in CNS segment.
--Malaysia
++**Malaysia**
  Laboratories Torrent (Malaysia) Sdn Bhd , a subsidiary of Torrent Pharma in Malaysia , kicked off its operations in March 2012 to further strengthen presence in the South East Asian Market. The major focus areas are CNS and CV therapies. Today, Torrent is one of the fastest growing companies in the country.
--MENA
++**MENA**
  The Middle East North Africa operations are spread across affluent markets like Bahrain, UAE and Yemen. Torrent Pharmaceuticals has about 40 registrations in these markets with a strong product portfolio in the pipeline. Torrent Pharma is expanding its operations in the MENA region and Torrent Pharmaceuticals has strategic tie-ups in Jordan, Qatar and Libya as well.
--Australia
++**Australia**
  Torrent Pharma has created a distinct presence in the Pacific region with its subsidiary - Torrent Australasia Pvt Ltd (TAPL). Torrent Pharmaceuticals has received 5 product approvals in the regulated markets of the region.
--LATIN AMERICA
++=== Latin America ===
--Mexico
++**Mexico**
  Torrent entered Mexico Market in 2010, primarily with CNS products. Today Torrent Pharmaceuticals is the 6th ranked company in the covered market. Torrent Pharmaceuticals is active amongst highest growing companies in the CNS segment. Torrent Pharmaceuticals has 26 registered products out of which 11 products are being marketed. Torrent Pharmaceuticals has been growing through intensive CRM with the key specialists like Neurologists, Psychiatrists and Geriatricians.
@@ -278,12
+278,12 @@
  In addition to continuing the consolidation in the CNS segment; the company aim to strengthen its business by launching new products in other therapeutic areas as well.
--Rest of Latin America & Caribbean markets
++**Rest of Latin America & Caribbean markets**
  Torrent aims to penetrate the Latin American market with its high quality products and extensive product portfolio. Strong economic performance in this region is expected to fuel its growth in the coming years. In addition, recent regulatory developments will create further market opportunities in these countries, particularly for generic producers in both the private and public sectors. With over 50 registrations in pipeline, Torrent is increasing its foothold in important markets like Venezuela, Colombia, Peru, Chile, Panama, Guatemala, Ecuador, Dominican Republic, Costa Rica, Honduras, Jamaica and Trinidad & Tobago
--Russia & CIS
++**Russia & CIS**
  Torrent Pharma’s foray into the international markets began with operations in the erstwhile Soviet Union in 1983. In Russian Federation, Torrent has a wholly owned subsidiary and its own warehouse for closer reach to the customers. Torrent, through its own field force of over 65 sales professionals has strong presence across major cities in Russia.
@@ -291,14
+291,16 @@
  With product registrations in Russia and CIS , Torrent has sizeable presence in therapeutic areas of Cardio Vascular, Neurology , Psychiatry and Gastroenterology.
--Industry Overview
++[[image:TORNTPHARM5.png]]
--Global Pharma Market
--Life science companies are facing unprecedented change. Their customers are changing, the nature of their products and sales models are changing, and they face new kinds of competitors. Budgetary pressures are affecting health care systems globally, payers are pushing back aggressively on prices and demanding evidence of value, and digitally empowered and increasingly informed patients are playing a more active role in their treatment. By 2025, many life science companies will have transitioned toward more patientcentric business models, offering products and services designed to improve outcomes and address the specific needs of empowered customers. The market will be characterised by mass customisation, enabled by continuous technological advancements and a host of new health care players.
++= Industry Overview =
--[[https:~~/~~/torrentpharma.com/pdf/download/AR-2020-21.pdf>>url:https://torrentpharma.com/pdf/download/AR-2020-21.pdf]]
++== Global Pharma Market ==
++Life science companies are facing unprecedented change. Their customers are changing, the nature of their products and sales models are changing, and they face new kinds of competitors. Budgetary pressures are affecting health care systems globally, payers are pushing back aggressively on prices and demanding evidence of value, and digitally empowered and increasingly informed patients are playing a more active role in their treatment. By 2025, many life science companies will have transitioned toward more patientcentric business models, offering products and services designed to improve outcomes and address the specific needs of empowered customers. The market will be characterised by mass customisation, enabled by continuous technological advancements and a host of new health care players.{{footnote}}https://torrentpharma.com/pdf/download/AR-2020-21.pdf{{/footnote}}
++
++
  Global medicine spending is expected to grow more slowly, but projected to exceed $1.1 trillion in the next five years
  The rise in spending is partly due to increased use, but is also driven by changes in the specialty and innovative product composition of new brands reaching the market. Other factors, such as pricing pressures and brand losses of exclusivity offset rises in spending. With these dynamics, spending growth is projected to slow in the next five years
@@ -309,8
+309,9 @@
  Brand LOEs are projected to have a $139 billion negative impact on brand sales from 2020–24, compared to the $107 billion impact seen from 2014–19
--Future of Generics
++== Future of Generics ==
++
  Generic medicine is designed to be identical as branded drugs, marketed by private companies in dosage form, strength, safety, route of administration, performance characteristics, quality, and intended use. Generic drugs work in the same way as branded drugs in terms of clinical benefits. Generic drugs are manufactured after the expiration of the exclusive rights or patent of the branded drugs.
  The global generic pharmaceuticals market is expected to grow from $233.66 billion in 2019-20 to $245.6 billion in 2020-21 at a compound annual growth rate (CAGR) of 5.1%.
@@ -324,7
+324,7 @@
  The market of the generic drugs consists of both Branded Generics and Non Branded Generics. Branded Generic drugs are marketed under another the company’s brand name but they are bioequivalent to their generic counterparts. It is expected that the global Branded Generics market will be led China, India and Asia Pacific (excluding Japan). Drugs for cardiovascular diseases and diabetes, which account for major share of Branded Generics sales in the global market, are projected to remain at the top over the next 10 years.
--Business Overview
++= Business Overview =
  Torrent Pharma is one of the front-runners in the Indian pharmaceuticals industry having presence in domestic as well as International markets. The Company has subsidiaries across the globe as under. The Company also has major commercial presence in other countries mainly covering Southeast Asia, Africa and the Middle East.

Applications

More applications

Recently Visited

Analysts

Photo	Name
	SGK India Engineering Private Limited
	Jeanpierre Pozo
	Robert Lakin
	Erich Richards
	Jason Adams
	Thomas Niel
	Md. Touhidul Islam
	Ajit Singh
	Buck Winston
	Asif Farooqui
	Wilton Risenhoover

View All

Recently Modified

This site is funded and maintained by Fintel.io

XWiki 12.2.1